Skip to content

Celldex Therapeutics CLDX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-35,688.5%-17,101pp-18,587.7%-8,732pp-9,855.4%-5,802pp-4,053.7%-1,180pp-2,873.5%-94.6pp
Net margin-32,753.6%-16,016pp-16,737.2%-8,101pp-8,635.8%-5,189pp-3,446.9%-1,081pp-2,366.1%-117pp
Returns
Return on equity-48.9%-8.3pp-40.6%-8.2pp-32.4%-5.3pp-27.2%-4.0pp-23.2%+3.6pp
Return on invested capital-55.6%-8.6pp-47%-8.1pp-38.9%-5.6pp-33.3%-2.6pp-30.7%+4.2pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.0×
Liquidity
Current ratio8.9×-1.6×10.5×-2.5×13×-6.7×19.7×-2.0×21.7×+2.8×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$6.85-13.6%$7.94-11.9%$9.01-8.7%$9.87-6.8%$10.59-8.7%
Valuation
Market capitalization$2.11B+17.0%$1.8B+5.1%$1.72B+19.5%$1.44B+19.3%$1.2B-28.1%
Price / sales2,438.2×+1,271×1,167.4×+507×660.7×+413×248.2×+88.8×159.4×-79.4×
Price / book4.6×+1.2×3.4×+0.6×2.9×+0.7×2.2×+0.5×1.7×-0.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Celldex Therapeutics's ratios come from?
Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.